home / stock / mnpr / mnpr quote
Last: | $0.65 |
---|---|
Change Percent: | -1.53% |
Open: | $0.65 |
Close: | $0.660101 |
High: | $0.675 |
Low: | $0.6357 |
Volume: | 19,499 |
Last Trade Date Time: | 05/01/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.65 | $0.65 | $0.660101 | $0.675 | $0.6357 | 19,499 | 05-01-2024 |
$0.660101 | $0.63 | $0.660101 | $0.69 | $0.63 | 54,655 | 04-30-2024 |
$0.65 | $0.68 | $0.65 | $0.68 | $0.6401 | 15,062 | 04-29-2024 |
$0.6582 | $0.63 | $0.6582 | $0.6671 | $0.63 | 35,008 | 04-26-2024 |
$0.6275 | $0.65 | $0.6275 | $0.65 | $0.62 | 58,241 | 04-25-2024 |
$0.657 | $0.68 | $0.657 | $0.68 | $0.63 | 38,739 | 04-24-2024 |
$0.65 | $0.618 | $0.65 | $0.6575 | $0.61 | 85,559 | 04-23-2024 |
$0.632 | $0.66 | $0.632 | $0.66 | $0.62 | 27,730 | 04-22-2024 |
$0.6401 | $0.678 | $0.6401 | $0.6799 | $0.6216 | 33,393 | 04-19-2024 |
$0.678 | $0.7 | $0.678 | $0.72 | $0.659 | 77,544 | 04-18-2024 |
$0.655 | $0.69 | $0.655 | $0.72 | $0.6501 | 151,084 | 04-17-2024 |
$0.728 | $0.73 | $0.728 | $0.740251 | $0.69 | 178,639 | 04-16-2024 |
$0.755 | $0.7599 | $0.755 | $0.781 | $0.7438 | 101,444 | 04-15-2024 |
$0.781 | $0.8 | $0.781 | $0.82 | $0.76 | 283,292 | 04-12-2024 |
$0.77 | $0.753 | $0.77 | $0.85 | $0.72 | 848,671 | 04-11-2024 |
$0.64 | $0.6189 | $0.64 | $0.6517 | $0.4999 | 457,696 | 04-10-2024 |
$0.5906 | $0.63 | $0.5906 | $0.63 | $0.5812 | 114,130 | 04-09-2024 |
$0.601 | $0.6 | $0.601 | $0.6341 | $0.5833 | 150,063 | 04-08-2024 |
$0.602 | $0.63 | $0.602 | $0.6399 | $0.599401 | 133,332 | 04-05-2024 |
$0.6384 | $0.6212 | $0.6384 | $0.68 | $0.6191 | 137,827 | 04-04-2024 |
News, Short Squeeze, Breakout and More Instantly...
Monopar Therapeutics Inc. Company Name:
MNPR Stock Symbol:
NASDAQ Market:
WILMETTE, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its abstract on the preclinical data for its radiopharmaceutical program MN...
WILMETTE, Ill., April 16, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused o...
WILMETTE, Ill., April 16, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that it has filed a provisional patent application pertaining to the recent adva...